Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03361228 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03361228 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 5 participants.
The verdict
NCT03361228, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Epacadostat
- DRUG INCB001158
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2019-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03361228
The ClinicalTrials.gov registry entry for NCT03361228 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03361228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03361228 about?
NCT03361228 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors". The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT03361228?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-03-01. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT03361228?
The interventions under investigation include: Pembrolizumab (DRUG), Epacadostat (DRUG), INCB001158 (DRUG).
Who is sponsoring clinical trial NCT03361228?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.